Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome
Fig 6
Effect of simulating different dosing protocols on CAR-T cell dynamics, tumor response, and cytokine peak. To investigate the outcomes of a different CAR-T dose or change in the preconditioning or bridging therapy, we compared the standard scenario (Fit) with simulations starting with either a different CAR-T dose or initial tumor burden (10x and 100x smaller and higher). Assessed outcomes were: A number of CAR-T cells at peak (), B number of tumor cells at day 28, C number of persister CAR-T cells at day 28 D IL-6 fold change (baseline to peak), E day of CAR-T cell peak, F day of IL-6 peak. The number of tumor and CAR-T persister cells at day 90 were also assessed and did not present sensible differences (S7 Fig).